AN2 Therapeutics, Inc.

NasdaqGS ANTX

AN2 Therapeutics, Inc. Shareholders' Equity for the quarter ending September 30, 2024

AN2 Therapeutics, Inc. Shareholders' Equity is NA for the quarter ending September 30, 2024. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

AN2 Therapeutics, Inc. Shareholders' Equity for the quarter ending September 30, 2022 was USD 105.57 M.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

NasdaqGS: ANTX

AN2 Therapeutics, Inc.

CEO	Mr. Eric E. Easom
IPO Date	March 25, 2022
Location	United States
Headquarters	1800 El Camino Real
Employees	41
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Key trends

Past 5 years